1. Introduction {#sec1}
===============

Medication-related osteonecrosis of the jaw (MRONJ) is an uncommon and potentially serious adverse side effect of antiresorptive and antiangiogenic agents \[[@B1]\]. It can cause chronic pain, infection, dysfunction, and disfigurement and can affect the quality of life of affected individuals \[[@B2], [@B3]\]. The vast majority of cases of MRONJ are associated with antiresorptive agents including bisphosphonates, denosumab, and more recently romosozumab \[[@B4]--[@B7]\]. A notably smaller number of cases are associated with the use of antiangiogenic agents, both in individuals who also take antiresorptive drugs and in those who are antiresorptive drugs-naïve \[[@B8]\]. MRONJ can develop in approximately 7% of cancer patients taking high-potency bisphosphonates or high-dose denosumab and about 0.01--0.1% of those with osteoporosis using low-potency oral bisphosphonates or low-dosage denosumab \[[@B1], [@B9]--[@B12]\]. The use of antiangiogenic agents in combination with antiresorptive drugs is known to increase the risk of MRONJ development \[[@B13]\]; however, little is known regarding the incidence and prevalence of antiangiogenic-related MRONJ in antiresorptive drugs-naïve individuals. Antiangiogenic inhibitors have been increasingly used in the management of a range of malignancies including ovarian cancer, metastatic renal cell cancer, breast cancer, colorectal cancer, non-small-cell lung cancer (NSCLC), and glioblastoma multiforme \[[@B14]\]. Antiangiogenic inhibitors can be categorised into three major groups based on their mechanism of action: anti-VEGF monoclonal antibody (e.g., bevacizumab), VEGF decoy receptors or VEGF-Trap (e.g., aflibercept), and small molecule tyrosine kinase inhibitors (TKI) that block the VEGF receptors downstream signaling pathways (e.g., sunitinib, cabozantinib, and sorafenib) \[[@B15]\] ([Table 1](#tab1){ref-type="table"}). Additionally, the mammalian target of rapamycin (mTOR) inhibitors also seems to have antiangiogenic effects by inhibiting the production of VEGF and platelet-derived growth factors (PDGF) \[[@B16]--[@B18]\].

The number of patients developing MRONJ associated with antiangiogenic inhibitors or a combination of antiangiogenics and antiresorptive drugs has been growing over the last few years \[[@B8], [@B13], [@B19], [@B20]\]. The purpose of the present study is to provide a comprehensive review of the published reports of MRONJ associated with antiangiogenic agents in patients with no history of antiresorptive therapies.

2. Materials and Methods {#sec2}
========================

2.1. Literature Search Strategy {#sec2.1}
-------------------------------

A literature search was conducted to identify clinical trials, case reports, and case series on MRONJ associated with antiangiogenic treatment in antiresorptive drugs-naïve individuals using MEDLINE via PubMed (up to December 2017), EMBASE (from 1980 to December 2017), and Web of Science (from 1900 to December 2017). The search strategy used the following keywords: "osteonecrosis," "jaw osteonecrosis," "jaw bone necrosis," "oral osteonecrosis," "antiangiogenic," "angiogenesis inhibitors," "antineoplastic agents," "antiangiogenic activity," "antiangiogenic therapy," "chemotherapy," and "targeted therapy." The references of retrieved articles were manually searched in order to identify additional relevant articles and abstracts. The search included articles published in English and other languages. Inclusion criteria were patients developing MRONJ associated with antiangiogenic agents based on the definition of MRONJ proposed by the special committee on MRONJ of the American Association of Oral and Maxillofacial Surgeons (AAOMS) in 2014 \[[@B1]\]. Patients with history of radiotherapy involving the jaw bones and patients having previous history or concurrent use of antiresorptive therapy were excluded.

3. Results {#sec3}
==========

3.1. Search Results {#sec3.1}
-------------------

A total of 4,597 articles were retrieved by the initial search, including literature reviews, duplicate articles, clinical trials, and case reports with bisphosphonates and antiangiogenic treatment. The flow chart of review process to identify studies included and excluded is shown in [Figure 1](#fig1){ref-type="fig"}. Following screening the articles, we identified 28 articles describing 35 cases of MRONJ meeting the aforementioned inclusion criteria. Of these 28 publications, 26 papers were published in English, one was published in Italian, and one was published in Japanese. These 35 reported MRONJ cases were related to previous history of treatment with bevacizumab (14 cases), aflibercept (5 cases), sunitinib (3 cases), cabozantinib (2 cases), sorafenib (1 case), temsirolimus (1 case), everolimus (1 case), dasatinib (1 case), and multiple antiangiogenic agents (7 cases) ([Table 2](#tab2){ref-type="table"}).

All 35 patients were reported to have developed MRONJ associated with at least one antiangiogenic agent and without a history of treatment with antiresorptive drugs. There were 19 males (54.29%) and 14 males (40%). The mean age of patients was 59.06 years (range: 33--80 years). The underlying diseases that required treatment with antiangiogenic agents included metastatic renal cell cancer (10 patients, 28.57%) followed by metastatic colorectal cancer (6 patients, 17.14%), metastatic breast cancer (5 patients, 14.29%), and other cancers (14 patients, 40%).

The most common presenting symptom was pain to the mandible/maxilla (12 patients, 34.29%) whereas 8 individuals (22.86%) reported no notable symptoms. The remaining patients had a variety of presenting complaints including mild discomfort to the mandible (1 patient, 2.86%), spontaneous teeth loss (1 patient, 2.86%), gingival bleeding (1 patient, 2.86%), and limited mouth opening together with submandibular swelling (1 patient, 2.86%). Moreover, there were 6 patients (17.14%) presenting with multiple symptoms including pain to the jaw, halitosis, spontaneous tooth loss, ulceration, difficulty in chewing, and paraesthesia. Regarding clinical characteristics of MRONJ, 32 patients (91.43%) had intraoral frank bone exposure, while the other three patients had nonexposed MRONJ. Mandible was the most common area of MRONJ development (29 patients, 82.86%), whereas four patients (11.43%) developed MRONJ in the maxilla.

Fourteen patients (40%) were exposed to bevacizumab, followed by aflibercept (5 patients, 14.29%), sunitinib (3 patients, 8.57%), cabozantinib (2 patients, 5.71%), sorafenib (1 patient, 2.86%), temsirolimus (1 patient, 2.86%), everolimus (1 patient, 2.86%), dasatinib (1 patient, 2.86%), and multiple antiangiogenic agents (7 patients, 20%). Regarding the routes of drug administration, antiangiogenic medications were administered intravenously in 21 patients (60.00%), while 12 patients (34.29%) were given antiangiogenic therapy orally. Two patients (5.71%) were given the combination of intravenous administration and oral administration. The mean duration of intravenous and oral antiangiogenic therapy before MRONJ development was 6.49 months (range: 0.23--36; SD = 1.82; 95% CI: 2.67--10.30) and 16.72 months (range: 1--60; SD = 6.42; 95% CI: 2.59--30.84), respectively. Patients with MRONJ also received a variety of concomitant medications including chemotherapy, hormone therapy, corticosteroids, antihypertensive drugs, antidepressants, and gastrointestinal medications.

Additional risk factors for MRONJ were reported in 21 patients, with dental extraction being the most prominent factor (13 patients, 37.14%). Other factors included history of mucosal trauma from dentures, chronic infection/inflammation to the tooth-bearing alveolar bone (periodontal disease), and insertion of osteointegrated dental implants (8 patients, 22.86%). The mean time to MRONJ diagnosis after tooth extraction was 3.09 months (range: 0.23--8; SD = 1.13; 95% CI: 0.40--5.77).

Regarding the management of MRONJ, seventeen patients (48.57%) were managed with surgical procedures alone or combined with medications (antibiotic therapy, antimicrobial mouthwash) and interruption of antiangiogenic agents. 16 patients did not receive surgery (45.71%), with antiangiogenic agents being discontinued in 7 cases. There was no active intervention reported in one patient. Most surgical interventions (11 patients) were minimally invasive procedures including smoothening of exposed bone, local flap coverage, removal of superficial necrotic bone, soft tissue debridement, and bone curettage, whereas 6 patients underwent major surgery such as bone decortication, resection of necrotic bone with local flap coverage, segmental osteotomy, and block resection. The outcomes of therapy were reported for 29 patients (82.8%), whereas no information was provided for the other 6 cases. 18 patients out of these 29 (62%) were reported to have disease resolution, while 11 patients showed persistent bone exposure. Disease resolution was described as complete mucosal coverage/no evidence of exposed bone in 13 cases, whereas no clear description was provided for the remaining 5 cases. Of note, one patient who experienced disease resolution to the left side of the mandible eventually developed a new area of MRONJ to the right mandible. The mean time from MRONJ diagnosis to complete healing was 6.75 months (range months: 1.84--22; SD = 2.47; 95% CI: 0.90--12.59). The data of 35 reported cases with MRONJ associated with antiangiogenics are summarised in [Table 3](#tab3){ref-type="table"}.

4. Discussion {#sec4}
=============

The present study is the first comprehensive review upon MRONJ in patients treated with antiangiogenics in the absence of bone-modulating therapy.

We present data from 35 patients with different metastatic cancers who developed MRONJ following antiangiogenic treatments. All individuals were antiresorptive drugs-naïve. We have identified a number of differences between MRONJ associated with antiangiogenic agents and MRONJ associated with antiresorptive drugs. Our data showed a sex ratio of 4 : 5 (F : M) and an age range of 33--80 years (mean: 59.06 years), compared to sex ratio of 3 : 2 and age range of 42--90 years (mean 66 years) reported for antiresorptive drugs-associated MRONJ \[[@B21]--[@B23]\]. There also seem to be differences in the prevalence of MRONJ in these two populations. The reported prevalence of MRONJ in patients who had been treated with intravenous bevacizumab alone for the treatment of advanced breast cancer was 0.2%, which was lower than that of MRONJ associated with intravenous antiresorptive agents (7%) \[[@B11], [@B19]\]. However, it is important to note that the prevalence of MRONJ related to antiangiogenic agents may also depend on the epidemiology of underlying malignancies that require antiangiogenic therapy.

The clinical presentations of MRONJ associated with antiangiogenics also seem to be different from MRONJ due to antiresorptive agents. Approximately up to 25% of MRONJ cases related to antiresorptive medications can present without frank bone exposure \[[@B24]\], whereas most of the patients in the present review had clear evidence of bone exposure (91.43%). However, the number of patients with nonexposed MRONJ might be underestimated, since until 2014 MRONJ could only be diagnosed in individuals with clinical evidence of exposed bone as per AAOMS definition \[[@B24], [@B25]\].

With respect to the presenting complaints and location, they appear to be similar in two populations. The majority of patients with antiangiogenic-related MRONJ in this study experienced pain to the jaw, which is also the most common complaint in patients with MRONJ associated with antiresorptive agents \[[@B22], [@B26]\]. In the present study, most MRONJ cases associated with antiangiogenic therapy tended to occur in the mandible more frequently than in the maxilla, similar to those with antiresorptive drugs-induced MRONJ \[[@B21], [@B23]\].

A number of additional risk factors were identified in the present review including dental extraction, the use of denture, periodontal infection, and dental implant. Almost 40% of reported cases in this study were predominantly preceded by tooth extraction, which is similar to those with antiresorptive drugs-related MRONJ \[[@B21], [@B27]\].

There is a slight difference with respect to underlying malignancies between two populations. Patients with antiresorptive drugs-associated MRONJ showed the previous history of multiple myeloma, metastatic breast cancer, and metastatic prostate cancer, whereas those with MRONJ related to antiangiogenic medications in our review were mainly diagnosed with metastatic renal cell cancer, followed by metastatic colorectal cancer and metastatic breast cancer as demonstrated in [Table 3](#tab3){ref-type="table"} \[[@B23]\].

Although there was no consistent pattern in the time to MRONJ development in this review, the average time for developing MRONJ among patients with either intravenous or oral antiangiogenics was shorter than the average time to MRONJ onset in those treated with antiresorptive drugs. The mean time to event for intravenous and oral antiangiogenic agents in this study was 6.5 and 16.71 months, respectively, while it was reported to be approximately 1.8 and 3 years for bisphosphonate therapy \[[@B12], [@B28]\].

Patients with metastatic malignancy may receive a number of anticancer drugs simultaneously. In this review, we found that seven of the reported cases received more than one antiangiogenic agent in their treatment history \[[@B35], [@B29]--[@B34]\]. Of these patients, some were given different antiangiogenics at the same time, while others received these agents at different time points. The development of MRONJ is usually associated with the latest antiangiogenic agent used by the patient; however, one cannot exclude the fact that the antiangiogenic agents previously used by these patients might have contributed to it.

We included in this review two cases of MRONJ associated with new TKIs, namely, pazopanib in combination with axitinib (*n* = 1) and dasatinib (*n* = 1) \[[@B35], [@B34]\]. According to the Food and Drug Administration\'s Adverse Event Reporting System (FAERS), pazopanib and axitinib have been associated with the development of MRONJ in 10 and 9 individuals, respectively; however, as data regarding concurrent or previous medication were not available in FAERS documentation \[[@B36]\], it is difficult to conclude whether these individuals were indeed antiresorptive drugs-naïve. Therefore, we decided not to include these 19 cases in our review.

With regard to the management of MRONJ, approximately half of the individuals with MRONJ associated with antiangiogenics (48.57%) were managed surgically, which is similar to those with bisphosphonate-related MRONJ \[[@B11], [@B23]\]. However, the prognosis of antiangiogenic-related MRONJ appears to be better than that of individuals developing MRONJ associated with antiresorptive agents. We observed a 62% rate of disease resolution in those where outcomes were reported as opposed to approximately 50% reported in the literature for MRONJ associated with antiresorptive agents \[[@B27], [@B37], [@B38]\]. It is possible that the higher rate of disease resolution might be related to the shorter half-life of antiangiogenics \[[@B39], [@B40]\], as well as the lower cumulative dosages \[[@B41]\]. Moreover, the average time to resolution for MRONJ associated with antiangiogenics appears to be shorter than antiresorptive drugs-induced MRONJ (6.75 months, range: 1.84--22 months versus 8.2 months, range: 0.2--25.6 months) \[[@B26]\].

In this comprehensive review, we excluded a number of potential antiangiogenic-related MRONJ cases due to a lack of adequate clinical information. For example, the 2012 report on aflibercept by the US Food and Drug Administration (FDA) described 3 aflibercept-treated bisphosphonate-naïve patients who developed MRONJ; however, none of these patients were added to the present review as one had jaw bone exposure for less than 8 weeks and no information was provided for the other two cases \[[@B42]\]. Furthermore, in a pivotal BOLERO-2 trial, MRONJ has been described in 2 patients in the experimental arm (everolimus-exemestane) and 1 patient in the control arm (exemestane), with one of three patients to receive bisphosphonate treatment \[[@B43]\]. However, there was no evidence to show whether the patient with a history of bisphosphonate treatment was in the experimental arm or control arm. More recently, Antonuzzo et al. \[[@B44]\] reported the first case with MRONJ potentially associated with regorafenib, one of the tyrosine kinase inhibitors, in an antiresorptive drugs-naïve individual. Although MRONJ appeared 22 months after regorafenib treatment, Fusco et al. \[[@B45]\] have noted that some details such as the use of other medications prior to regorafenib treatment, dosing, and the time on medication are still missing. This medication is usually used as a third or further line of treatment of metastatic colorectal cancer. Therefore, it is also worth knowing whether this patient has received other well-documented antiangiogenic medications such as bevacizumab and aflibercept prior to regorafenib. If this is the case, bevacizumab or aflibercept possibly might contribute to the development of MRONJ rather than regorafenib alone. Another patient with gastrointestinal stromal tumours (GISTs) receiving imatinib monotherapy presented with pain and exposed bone at lower right mandible after having the tooth removed for 5 weeks. The patient was treated with debridement of necrotic bone and antibiotic and then was discharged. Unfortunately, there was no further information about this patient \[[@B46]\]. The duration of persistent bone exposure in this case was not mentioned if it was longer than 8 weeks. Therefore, available data seems not to be enough to classify this case as MRONJ according to the definition of MRONJ \[[@B1]\] and to confirm the association between MRONJ and imatinib. In addition to the above reported cases, Hopp et al. \[[@B47]\] reported one patient with necrotic bone exposure after the 2-year intravitreal injections of bevacizumab for treatment of retinal vascular thrombosis without notable dental risk factors or use of bisphosphonates. After the patient experienced pain to the mandible, the lesion was completely healed by antibiotics treatment within 8 weeks. Therefore, this case seems not to be correlated with the definition of MRONJ formulated by the AAOMS in 2014 \[[@B1]\].

It is important to highlight that another case of oral soft tissues complication associated with bevacizumab was also reported by Magremanne et al. \[[@B48]\]. Although this case was included in previous reviews regarding cases of MRONJ associated with antiangiogenic agents, there was no evidence of osteonecrosis of the jaw and also the necrotic area seemed to be limited only to oral soft tissues. This reported case does not meet the definition of MRONJ and hence it was excluded from this review.

5. Conclusion {#sec5}
=============

There remains incomplete information regarding the cases of antiangiogenic-related MRONJ in antiresorptive-naïve individuals reported in the literature. It is therefore difficult to draw any conclusion regarding the epidemiology and the characteristics of MRONJ in this patient population. Within the limitation of available data, we have identified a number of differences between MRONJ associated with antiangiogenics and MRONJ related to antiresorptive drugs including demographic characteristics, prevalence, the underlying malignant disease, time to the onset, and time to resolution. Considering that the list of antiangiogenic inhibitors that have potential to increase the risk of MRONJ development is increasing, further prospective and well-designed research is warranted to confirm our findings and increase knowledge and understanding of the disease.
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###### 

Approved antiangiogenic medications \[[@B14], [@B15], [@B49], [@B50]\].

  Approved antiangiogenic drugs                                                                  
  ---------------------------------------------------------------------------------------------- ------------------------------------------------
  *Anti-VEGF monoclonal antibody*                                                                *Indications for use*
  Bevacizumab                                                                                    Metastatic colorectal cancer
  Non-small-cell lung cancer                                                                     
  Glioblastoma multiforme                                                                        
  Metastatic renal cell cancer                                                                   
  Macular degeneration                                                                           
  Metastatic HER2 negative breast cancer                                                         
  Persistent, recurrent, and metastatic cervical cancer                                          
  Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer   
                                                                                                 
  *VEGF decoy receptor (VEGF-Trap)*                                                              *Indications for use*
  Aflibercept                                                                                    Metastatic colorectal cancer
                                                                                                 
  *Tyrosine kinase inhibitors*                                                                   *Indications for use*
  Sorafenib                                                                                      Metastatic renal cell cancer
  Hepatic cancer (hepatocellular carcinoma)                                                      
  Sunitinib                                                                                      Metastatic renal cell carcinoma
  Gastrointestinal stromal tumour                                                                
  Pancreatic neuroendocrine tumour                                                               
  Cabozantinib                                                                                   Medullary thyroid cancer
  Erlotinib                                                                                      Non-small-cell lung cancer
  Pancreatic cancer                                                                              
  Axitinib                                                                                       Metastatic renal cell cancer
  Pegaptanib                                                                                     Macular degeneration
  Ranibizumab                                                                                    Macular degeneration
  Pazopanib                                                                                      Metastatic renal cell cancer
  Soft tissue sarcoma                                                                            
  Vandetanib                                                                                     Medullary thyroid cancer
  Regorafenib                                                                                    Metastatic colorectal cancer
  Gastrointestinal stromal tumour                                                                
  Imatinib                                                                                       Chronic myeloid leukemia
  Renal cell cancer                                                                              
  Gastrointestinal stromal tumour                                                                
  Dasatinib                                                                                      Philadelphia chromosome-positive (Ph+) chronic
  myeloid leukemia (CML)                                                                         
  Chronic phase Ph+ CML                                                                          
  Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (Ph+ ALL)                  
                                                                                                 
  *Mammalian target of rapamycin inhibitors (mTOR inhibitors)*                                   *Indications for use*
  Temsirolimus                                                                                   Renal cell cancer
  Everolimus                                                                                     Advanced breast cancer
  Advanced renal cell cancer                                                                     
  Pancreatic neuroendocrine tumour                                                               
  Tuberous sclerosis complex                                                                     
  Subependymal giant cell astrocytoma                                                            

###### 

Previously reported cases of MRONJ associated with antiangiogenic medications (*n* = 35).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Number   Authors                          Age   Sex   Diagnosis of cancer                                           Treatment and concurrent medications   Antiangiogenic agents                                    Symptoms                                                        Clinical presentation   Site of MRONJ   Time to MRONJ                                                  Predisposing factors                        Management of MRONJ                                                              Outcomes                                      Definition of disease resolution
  -------- -------------------------------- ----- ----- ------------------------------------------------------------- -------------------------------------- -------------------------------------------------------- --------------------------------------------------------------- ----------------------- --------------- -------------------------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------------- --------------------------------------------- --------------------------------------
  \(1\)    Estilo et al. \[[@B51]\]         51    F     Metastatic breast cancer                                      Mastectomy\                            Bevacizumab\                                             Jaw discomfort                                                  Bone exposure           Mandible        18 weeks\                                                      None                                        Surgical treatment\                                                              Disease resolution (few weeks)\               Complete mucosal coverage
                                                                                                                      Chest wall resection\                  15 mg/kg\                                                                                                                                                        after starting bevacizumab                                                                                 (smoothen exposed bone)\                                                         Developed new MRONJ lesion (right mandible)   
                                                                                                                      Chest wall radiation\                  every 3 weeks\                                                                                                                                                                                                                                                              Chlorhexidine mouthwash 0.12%\                                                                                                 
                                                                                                                      Doxorubicin\                           (total 8 doses)                                                                                                                                                                                                                                                             Interruption of bevacizumab                                                                                                    
                                                                                                                      Cyclophosphamide\                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                      Letrozole\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                      Paclitaxel\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      Capecitabine                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(2\)    Estilo et al. \[[@B51]\]         33    F     Glioblastoma multiforme                                       Surgical resection\                    Bevacizumab\                                             Jaw pain\                                                       Bone exposure           Mandible        11 weeks\                                                      None                                        None                                                                             Persistent bone exposure\                     ---
                                                                                                                      Radiotherapy\                          15 mg/kg\                                                (gingival pain)                                                                                         after starting bevacizumab                                                                                                                                                                  (3 months)                                    
                                                                                                                      Temozolomide                           every 2 weeks                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(3\)    Greuter et al. \[[@B52]\]        63    F     Metastatic breast cancer                                      Liposomal-doxorubicin                  Bevacizumab                                              Maxillary pain                                                  Bone exposure           Maxilla         2 months\                                                      Extraction due to dental infection\         Surgical treatment                                                               Disease resolution                            Not specified
                                                                                                                                                                                                                                                                                                                              after starting bevacizumab                                     (1 month)                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(4\)    Serra et al. \[[@B53]\]          64    M     Metastatic non-small-cell lung cancer                         Pneumectomy\                           Bevacizumab\                                             Jaw pain                                                        Bone exposure           Mandible        1 week\                                                        Extraction\                                 Surgical treatment\                                                              Persistent bone exposure\                     ---
                                                                                                                      Lymph node ablation\                   7.5 mg/kg                                                                                                                                                        after starting bevacizumab                                     (1 week)                                    (local flap coverage)\                                                           (3.5 months)                                  
                                                                                                                      Cisplatin\                                                                                                                                                                                                                                                                                                         Amoxicillin with clavulanate\                                                                                                  
                                                                                                                      Gemcitabine                                                                                                                                                                                                                                                                                                        Chlorhexidine mouthwash 0.2%                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(5\)    Guarneri et al. \[[@B19]\]       NA    NA    Metastatic breast cancer                                      Docetaxel                              Bevacizumab\                                             NA                                                              Bone exposure           Mandible        7 months\                                                      None                                        Surgical treatment\                                                              Disease resolution\                           Complete mucosal coverage
                                                                                                                                                             7.5 mg/kg or\                                                                                                                                                    after starting bevacizumab                                                                                 (mandible decortication, tooth extraction)\                                      (6 months)                                    
                                                                                                                                                             15 mg/kg every 3 weeks                                                                                                                                                                                                                                                      Interruption of bevacizumab                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(6\)    Guarneri et al. \[[@B19]\]       NA    NA    Metastatic breast cancer                                      Docetaxel                              Bevacizumab\                                             NA                                                              Bone exposure           NA              2 months\                                                      None                                        NA                                                                               NA                                            ---
                                                                                                                                                             7.5 mg/kg or\                                                                                                                                                    after starting bevacizumab                                                                                                                                                                                                                
                                                                                                                                                             15 mg/kg every 3 weeks                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(7\)    Brunamonti\                      47    M     Adenocarcinoma of parotid gland                               Surgical treatment\                    Bevacizumab\                                             Jaw pain, paraesthesia                                          Bone exposure           Mandible        16 months\                                                     Symptomatic eruption of lower third molar   Surgical treatment\                                                              Persistent bone exposure\                     ---
           Binello et al. \[[@B54]\]                                                                                  Epirubicin\                            15 mg/kg\                                                                                                                                                        after starting bevacizumab                                                                                 (removed necrotic bone)\                                                         (7 months)                                    
                                                                                                                      Cisplatin                              (total 8 doses in\                                                                                                                                                                                                                                                          Amoxicillin with clavulanate\                                                                                                  
                                                                                                                                                             6 months)                                                                                                                                                                                                                                                                   Metronidazole                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(8\)    Bettini et al. \[[@B55]\]        57    F     Metastatic non-small-cell lung cancer                         Gemcitabine\                           Bevacizumab\                                             Jaw pain,\                                                      Bone exposure           Mandible        2 months\                                                      Periodontal infection                       Amoxicillin with clavulanate\                                                    Disease resolution                            Complete mucosal coverage
                                                                                                                      Cisplatin\                             945 mg/21 days\                                          halitosis, tooth loss                                                                                   after starting bevacizumab                                                                                 Lincomycin (for 7 days)                                                                                                        
                                                                                                                      Corticosteroid                         4 cycles                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(9\)    Dişel et al. \[[@B56]\]          51    M     Metastatic colon cancer                                       5-Fluorouracil\                        Bevacizumab\                                             Jaw pain, ulcer, difficulty in chewing                          Bone exposure           Mandible        NA                                                             None                                        Surgical treatment\                                                              NA                                            ---
                                                                                                                      Leucovorin\                            5 mg/kg\                                                                                                                                                                                                                                                                    (bone curettage)                                                                                                               
                                                                                                                      Oxaliplatin                            every 2 weeks                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(10\)   Sato et al.\                     67    M     Metastatic sigmoid colon cancer                               Surgical treatment\                    Bevacizumab                                              Jaw pain                                                        Nonexposed MRONJ        Maxilla         3 months\                                                      Extraction\                                 Surgical treatment\                                                              Disease resolution                            Complete mucosal coverage
           \[[@B57]\]                                                                                                 Oxaliplatin\                                                                                                                                                                                            after starting bevacizumab                                     (1 month)                                   (removal of necrotic tissue)\                                                                                                  
                                                                                                                      Leucovorin\                                                                                                                                                                                                                                                                                                        Antibiotics                                                                                                                    
                                                                                                                      Irinotecan\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      5-Fluorouracil                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(11\)   Fusco et al. \[[@B58]\]          60    M     Metastatic rectal cancer                                      Surgical treatment\                    Bevacizumab                                              Jaw pain                                                        Bone exposure           Mandible        9 months\                                                      Extraction\                                 Antibiotics\                                                                     NA                                            ---
                                                                                                                      Radiotherapy\                                                                                                                                                                                           after starting bevacizumab                                     (8 months)                                  Chlorhexidine mouthwash                                                                                                        
                                                                                                                      5-Fluorouracil\                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                      Leucovorin\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      Irinotecan\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      Oxaliplatin                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(12\)   Tzermpos et al. \[[@B59]\]       69    M     Metastatic non-small-cell lung cancer                         Carboplatin\                           Bevacizumab\                                             Jaw pain, discomfort, paraesthesia                              Bone exposure           Mandible        3 years\                                                       Denture                                     Surgical treatment\                                                              Disease resolution (8 weeks)                  Complete mucosal coverage
                                                                                                                      Docetaxel\                             15 mg/kg\                                                                                                                                                        after starting bevacizumab                                                                                 (surgical debridement)\                                                                                                        
                                                                                                                      Cortisone                              every 3 weeks                                                                                                                                                                                                                                                               Amoxicillin\                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                         Metronidazole\                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                         Chlorhexidine mouthwash 0.12%\                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                         Interruption of bevacizumab                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(13\)   Abel Mahedi\                     55    F     Non-small-cell lung cancer                                    Corticosteroids                        Bevacizumab                                              Asymptomatic                                                    Bone exposure           Maxilla         1.5 months after starting bevacizumab                          Extraction                                  Conservative treatment                                                           Disease resolution                            Not specified
           Mohamed\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
           et al. \[[@B35]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(14\)   Abel Mahedi\                     66    M     Glioblastoma multiforme                                       Corticosteroids                        Bevacizumab                                              Pain                                                            Nonexposed MRONJ        Mandible        1.5 months after starting bevacizumab                          Trauma                                      Conservative treatment\                                                          Disease resolution                            Not specified
           Mohamed\                                                                                                                                                                                                                                                                                                                                                                                                                      (antibiotic treatment)                                                                                                         
           et al. \[[@B35]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(15\)   Ponzetti et al. \[[@B60]\]       64    F     Metastatic colorectal cancer                                  5-Fluorouracil\                        Aflibercept                                              Spontaneous teeth loss with purulent discharge                  Bone exposure           Mandible        22 weeks\                                                      Periodontal infection                       Laser treatment                                                                  Persistent bone exposure                      ---
                                                                                                                      Irinotecan                                                                                                                                                                                              after starting\                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                              aflibercept                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(16\)   Mawardi et al. \[[@B61]\]        43    M     Metastatic colorectal cancer                                  5-Fluorouracil\                        Aflibercept                                              Jaw pain                                                        Bone exposure           Mandible        32 weeks after starting aflibercept                            None                                        Amoxicillin\                                                                     Persistent bone exposure\                     ---
                                                                                                                      Leucovorin\                                                                                                                                                                                                                                                                                                        Chlorhexidine mouthwash                                                          (1.5 months)                                  
                                                                                                                      Irinotecan                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(17\)   Mawardi et al. \[[@B61]\]        63    M     Metastatic carcinoid cancer                                   NA                                     Aflibercept                                              Asymptomatic                                                    Bone exposure           Mandible        46 weeks after starting aflibercept                            None                                        Amoxicillin with clavulanate\                                                    Persistent bone exposure (2.5 months)         ---
                                                                                                                                                                                                                                                                                                                                                                                                                                         Chlorhexidine mouthwash                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(18\)   Mawardi et al. \[[@B61]\]        51    M     Metastatic esophageal cancer                                  5-Fluorouracil\                        Aflibercept                                              Jaw pain                                                        Bone exposure           Mandible        14 weeks after starting aflibercept                            Extraction\                                 Amoxicillin\                                                                     Persistent bone exposure (2 months)           \-
                                                                                                                      Leucovorin\                                                                                                                                                                                                                                                            (2 weeks)\                                  Chlorhexidine mouthwash\                                                                                                       
                                                                                                                      Oxaliplatin                                                                                                                                                                                                                                                                                                        Nonsurgical sequestrectomy                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(19\)   Zarringhalam et al. \[[@B62]\]   47    M     Metastatic colorectal, peritoneum, liver, and pelvic cancer   None                                   Aflibercept                                              Asymptomatic                                                    Bone exposure           Mandible        4 weeks after starting aflibercept                             None                                        Surgical treatment\                                                              Persistent bone exposure (12 weeks)           ---
                                                                                                                                                                                                                                                                                                                                                                                                                                         (smoothen sharp exposed bone)                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(20\)   Nicolatou-Galitis\               64    F     Metastatic renal cell cancer                                  Nephrectomy\                           Sunitinib\                                               Jaw pain                                                        Bone exposure           Mandible        4 years\                                                       Denture                                     Amoxicillin\                                                                     Disease resolution (3 months)                 Complete mucosal coverage
           et al. \[[@B63]\]                                                                                          T4 replacement therapy\                50 mg/day for 4 weeks on and 2 weeks off (for 4 years)                                                                                                           after starting sunitinib                                                                                   Chlorhexidine mouthwash\                                                                                                       
                                                                                                                      Prednisolone\                                                                                                                                                                                                                                                                                                      Azithromycin\                                                                                                                  
                                                                                                                      (50 mg/day)                                                                                                                                                                                                                                                                                                        Interruption of sunitinib                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(21\)   Fleissig et al. \[[@B64]\]       58    F     Metastatic renal cell cancer                                  Nephrectomy\                           Sunitinib 50 mg/day for 4 weeks on and\                  Limited mouth opening, submandibular swelling, pain             Bone exposure           Mandible        10 months\                                                     Extraction\                                 Amoxicillin with clavulanate (IV)\                                               Disease resolution (18 weeks)                 Complete mucosal coverage
                                                                                                                      Thyroxin sodium                        2 weeks off                                                                                                                                                      after starting sunitinib                                       (8 months)                                  PenG (IV) for 6 weeks and oral amoxicillin for 6 weeks\                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                         Interruption of sunitinib                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(22\)   Melloni et al. \[[@B65]\]        62    M     Metastatic renal cell cancer                                  NA                                     Sunitinib 50 mg/day for 4 weeks on and\                  Jaw pain and infected lesion to the cutaneous side of the jaw   Bone exposure           Mandible        5 years\                                                       None                                        Surgical treatment\                                                              Disease resolution (12 months)                Complete mucosal coverage
                                                                                                                                                             2 weeks off                                                                                                                                                      after starting sunitinib                                                                                   (surgical sequestrectomy, ablation of necrotic bone, and local flap coverage)\                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                         Amoxicillin with clavulanate\                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                         Ofloxacin\                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                         Interruption of sunitinib                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(23\)   Tempia Valenta\                  51    F     Medullary thyroid cancer                                      NA                                     Cabozantinib                                             NA                                                              Bone exposure           Mandible        6 months\                                                      Extraction                                  Surgical treatment\                                                              Disease resolution (22 months)                Not specified
           et al. \[[@B66]\]                                                                                                                                                                                                                                                                                                  after starting cabozantinib                                                                                (surgical debridement)\                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                         Amoxicillin and clavulanate\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                         Chlorhexidine mouthwash 0.2%                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(24\)   Marino et al. \[[@B67]\]         51    F     Medullary thyroid cancer                                      Thyroidectomy\                         Cabozantinib\                                            Asymptomatic                                                    Bone exposure           Mandible        3 months\                                                      Extraction due to dental infection\         Surgical treatment\                                                              Disease resolution                            Complete mucosal coverage
                                                                                                                      5-Fluorouracil\                        (175 mg/day)                                                                                                                                                     after starting cabozantinib                                    (3 months)\                                 (segmental ostectomy and tooth extraction)\                                                                                    
                                                                                                                      Dacarbazine\                                                                                                                                                                                                                                                                                                       Amoxicillin and clavulanate\                                                                                                   
                                                                                                                      Radiotherapy\                                                                                                                                                                                                                                                                                                      Chlorhexidine mouthwash 0.2%                                                                                                   
                                                                                                                      Levothyroxine\                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                      Calcitriol\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      Vitamin D3\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      Duloxetine\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      Propranolol\                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                      Lansoprazole\                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                      Loperamide                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(25\)   Garuti et al. \[[@B68]\]         74    M     Metastatic hepatocellular carcinoma                           Furosemide\                            Sorafenib\                                               Asymptomatic                                                    Nonexposed MRONJ        Mandible        3 months after starting sorafenib                              None                                        Interruption of sorafenib                                                        Persistent bone exposure\                     ---
                                                                                                                      Potassium canrenoate\                  400 mg/day                                                                                                                                                                                                                                                                                                                                                   (3 months)                                    
                                                                                                                      Bisoprolol\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      Allopurinol\                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                      Tamsulosin\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      Hydroxychloroquine\                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                      Vitamin D\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                      Sertraline                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(26\)   Abel Mahedi\                     53    F     Acute lymphoblastic leukemia\                                 Corticosteroids                        Dasatinib                                                Pain                                                            Bone exposure           Mandible        5 months after starting dasatinib                              Extraction                                  Surgical treatment (block resection)                                             Disease resolution                            Not specified
           Mohamed\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
           et al. \[[@B35]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(27\)   Parti et al. \[[@B69]\]          60    M     Metastatic renal cell cancer                                  Nephrectomy\                           Temsirolimus\                                            NA                                                              Bone exposure           Mandible        3 months\                                                      Extraction\                                 Interruption of temsirolimus                                                     NA                                            ---
                                                                                                                      Prostatectomy                          25 mg every week\                                                                                                                                                after starting\                                                (3 months)                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                              temsirolimus                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(28\)   Yamamoto\                        80    F     Metastatic breast cancer                                      Capecitabine\                          Everolimus                                               Jaw pain, localised heat, tenderness                            Bone exposure           Mandible        2 months after starting everolimus                             None                                        Interruption of everolimus                                                       Persistent bone exposure (2 months)           ---
           et al. \[[@B70]\]                                                                                          Tamoxifen\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                      Fulvestrant\                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                      Exemestane                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(29\)   Agostino et al. \[[@B29]\]       73    M     Metastatic renal cell cancer                                  Nephrectomy                            \(1\) Sunitinib\                                         NA                                                              NA                      NA              12 months\                                                     NA                                          Interruption of bevacizumab                                                      NA                                            ---
                                                                                                                                                             50 mg/day for 4 weeks of 6-week cycle\                                                                                                                           after starting\                                                                                                                                                                                                                           
                                                                                                                                                             (2) Temsirolimus 25 mg every week\                                                                                                                               bevacizumab                                                                                                                                                                                                                               
                                                                                                                                                             (3) Bevacizumab 10 mg/kg every two weeks                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(30\)   Koch et al. \[[@B30]\]           59    M     Metastatic renal cell cancer                                  Nephrectomy\                           \(1\) Sorafenib\                                         Asymptomatic                                                    Bone exposure           Mandible        51 months\                                                     Extraction\                                 Surgical treatment\                                                              Disease resolution                            Complete mucosal coverage
                                                                                                                      Interferon\                            (2) Sunitinib\                                                                                                                                                   after starting\                                                (2 months)                                  (ablation of necrosis and local flap coverage)                                                                                 
                                                                                                                      Vinblastine\                           50 mg/day for\                                                                                                                                                   sunitinib                                                                                                                                                                                                                                 
                                                                                                                      Ramipril\                              4 weeks and then sunitinib\                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                      Hydrochlorothiazide\                   37.5 mg/day                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                      Metoprolol\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      I-Thyroxin                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(31\)   Santos-Silva et al. \[[@B31]\]   61    M     Metastatic renal cell cancer                                  Nephrectomy\                           \(1\) Bevacizumab\                                       Jaw pain                                                        Bone exposure           Mandible        55 weeks\                                                      None                                        Chlorhexidine mouthwash 0.12%\                                                   Disease resolution (3 months)                 The absence of exposed necrotic bone
                                                                                                                      Hydrochlorothiazide\                   10 mg/kg every 2 weeks\                                                                                                                                          after starting\                                                                                            Interruption of bevacizumab and temsirolimus                                                                                   
                                                                                                                      Captopril                              (2) Temsirolimus\                                                                                                                                                bevacizumab and temsirolimus                                                                                                                                                                                                              
                                                                                                                                                             25 mg every week                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(32\)   Pakosch et al. \[[@B32]\]        53    F     Pancreatic cancer                                             Surgical treatment\                    \(1\) Bevacizumab\                                       Jaw pain                                                        Bone exposure           Mandible        4 months\                                                      Denture                                     Surgical treatment\                                                              Disease resolution (2 months)                 Complete mucosal coverage
                                                                                                                      Gemcitabine\                           (2) Sorafenib                                                                                                                                                    after starting bevacizumab and sorafenib                                                                   (decortication),\                                                                                                              
                                                                                                                      Leucovorin\                                                                                                                                                                                                                                                                                                        Amoxicillin with clavulanate\                                                                                                  
                                                                                                                      5-Fluorouracil\                                                                                                                                                                                                                                                                                                    Chlorhexidine mouthwash\                                                                                                       
                                                                                                                      Oxaliplatin\                                                                                                                                                                                                                                                                                                       Solcoseryl\                                                                                                                    
                                                                                                                      Paclitaxel\                                                                                                                                                                                                                                                                                                        Interruption of bevacizumab and chemotherapy                                                                                   
                                                                                                                      Erlotinib                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(33\)   Jung \[[@B33]\]                  62    F     Renal cell cancer                                             Nephrectomy                            \(1\) Pazopanib\                                         Gingival bleeding and sore gum                                  Bone exposure           Mandible        7 weeks after starting everolimus                              Dental implant                              Cephalosporin\                                                                   Disease resolution                            Complete mucosal coverage
                                                                                                                                                             (2) Everolimus                                                                                                                                                                                                                                                              Surgical treatment\                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                         (sequestrectomy and internal fixation)                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(34\)   Patel et al. \[[@B34]\]          67    M     Metastatic renal cell cancer                                  Nivolumab\                             \(1\) Pazopanib\                                         Asymptomatic                                                    Bone exposure           Maxilla         1 months after starting axitinib                               None                                        Hydrogen peroxide mouthwash                                                      NA                                            ---
                                                                                                                      Amlodipine\                            (2) Axitinib                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                      Ramipril\                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                      Levetiracetam\                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                      Dexamethasone\                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                      Lansoprazole\                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                      Morphine\                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                      Metoclopramide\                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                      Amiodarone\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                      Cholecalciferol                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \(35\)   Abel Mahedi\                     70    M     Renal cell cancer                                             Corticosteroids                        \(1\) Sunitinib\                                         Asymptomatic                                                    Bone exposure           Mandible        10 months after starting sunitinib, everolimus was commenced   Extraction                                  Conservative treatment                                                           Persistent bone exposure                      ---
           Mohamed\                                                                                                                                          (2) Everolimus                                                                                                                                                                                                                                                                                                                                                                                             
           et al. \[[@B35]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not available.

###### 

Summary of data of reported cases of antiangiogenic-related MRONJ (*n* = 35).

  -------------------------------------------------------------------- ---------------------
  Age (years, range)                                                    
   Mean                                                                59.06 (33--80)
  Gender (*n*, %)                                                       
   Male                                                                19 (54.29%)
   Female                                                              14 (40.00%)
   NA                                                                  2 (5.71%)
  Diagnosis of cancers (*n*, %)                                         
   Metastatic renal cell cancer                                        10 (28.57%)
   Metastatic colorectal cancer                                        6 (17.14%)
   Metastatic breast cancer                                            5 (14.29%)
   Other cancers                                                       14 (40.00%)
    Metastatic non-small-cell lung cancer                              4
    Glioblastoma multiforme                                            2
    Medullary thyroid cancer                                           2
    Malignant parotid tumour                                           1
    Pancreatic cancer                                                  1
    Metastatic hepatocellular carcinoma                                1
    Metastatic carcinoid cancer                                        1
    Metastatic oesophageal cancer                                      1
  Presenting complaints (*n*, %)                                        
   Jaw pain                                                            12 (34.29%)
   Jaw pain with other complaints                                      6 (17.14%)
   Asymptomatic                                                        8 (22.86%)
   Jaw discomfort                                                      1 (2.86%)
   Spontaneous teeth loss                                              1 (2.86%)
   Limited mouth opening and submandibular area swelling               1 (2.86%)
   Gingival bleeding                                                   1 (2.86%)
   NA                                                                  5 (14.29%)
  Clinical presentation (*n*, %)                                        
   Bone exposure MRONJ                                                 32 (91.43%)
   Nonexposed MRONJ                                                    3 (8.57%)
  Location                                                              
   Mandible                                                            29 (82.86%)
   Maxilla                                                             4 (11.43%)
   NA                                                                  2 (6.67%)
  Types of antiangiogenic agents (*n*, %)                               
   Bevacizumab                                                         14 (40%)
   Aflibercept                                                         5 (14.29%)
   Sunitinib                                                           3 (8.57%)
   Cabozantinib                                                        2 (5.71%)
   Sorafenib                                                           1 (2.86%)
   Temsirolimus                                                        1 (2.86%)
   Everolimus                                                          1 (2.86%)
   Dasatinib                                                           1 (2.86%)
   Multiple antiangiogenic agents                                      7 (20.00%)
  Route of antiangiogenic administrations (*n*, %)                      
   Intravenous administration                                          21 (60.00%)
   Oral administration                                                 12 (34.29%)
   Combination of intravenous administration and oral administration   2 (5.71%)
  Time to MRONJ (months, 95% CI)                                        
   Intravenous antiangiogenics                                         6.49 (2.67--10.30)
   Oral antiangiogenics                                                16.72 (2.59--30.84)
  Predisposing factors (*n*, %)                                         
   Extraction                                                          13 (37.14%)
   Periodontal disease                                                 3 (8.57%)
   Minor trauma from use of denture                                    4 (11.43%)
   Dental implant                                                      1 (2.86%)
   Mean time to MRONJ after extraction (months, 95% CI)                3.09 (0.40--5.77)
  Management of MRONJ (*n*, %)                                          
   Surgical treatment                                                  17 (48.57%)
    Minimally invasive surgical procedures                             11
    Major surgical procedures                                          6
   Nonsurgical treatment                                               16 (45.71%)
   No treatment                                                        1 (2.86%)
   NA                                                                  1 (2.86%)
  Treatment outcomes (*n*, %)                                           
   Disease resolution                                                  18 (62.06%)
   Mean time to resolution (months, 95% CI)                            6.75 (0.90--12.59)
   Incomplete resolution                                               11 (37.93%)
   NA                                                                  6
  -------------------------------------------------------------------- ---------------------

NA: not available.
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